<DOC>
	<DOC>NCT01872078</DOC>
	<brief_summary>To assess the effects of AZD4901 when given in multiple doses to females with Polycystic Ovary Syndrome</brief_summary>
	<brief_title>A Study of AZD4901 in Females With Polycystic Ovary Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<criteria>Female patients between the ages of 18 to 45 years (inclusive). Suitable veins for cannulation or repeated venipuncture. Body mass index (BMI) between 18 and 40 kg/m2 (inclusive). A diagnosis of polycystic ovary disease. Amenorrhea or oligomenorrhea (defined as ≤ 6 menses per year). Negative serum pregnancy test at screening. Negative urine pregnancy test before randomisation. Not be breastfeeding. Not have been pregnant within the 6 months prior to screening. Perimenopausal or reached natural menopause, defined as FSH &gt; 10 IU/L. Menstruated within the month prior to the baseline visit. Hysterectomy or bilateral oophorectomy or both. Clinically relevant disease and abnormalities (past or present), and in particular causes of abnormal vaginal bleeding. Withdrawals from oral contraceptives if their LH levels are below 3 IU/L when retested within 7 ± 1 days of the baseline visit.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Pharmacokinetics, Pharmacodynamics, endocrinopathies, PCOS, female, hormone, LH</keyword>
</DOC>